Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL Cancer Network The progression-free survival (PFS) rate at 24 weeks was 93% for patients treated with idelalisib plus rituximab compared with 46% for patients treated with rituximab alone. The median PFS of the combination arm has not yet been reached. The median PFS ... Idelalisib plus rituximab extended survival in previously treated CLL Gilead's Pipeline Encourages |
